{
    "organizations": [],
    "uuid": "aff0aecdc6c04449f9d2e9ad0a1c461c5e65478a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sinclair-pharma-fy-sales-of-453-mi/brief-sinclair-pharma-fy-sales-of-45-3-million-idUSFWN1S702D",
    "ord_in_thread": 0,
    "title": "BRIEF-Sinclair Pharma FY Sales Of £45.3 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Sinclair Pharma PLC:\n* FY GROSS PROFIT INCREASED 23% TO £32.9 MILLION * SINCLAIR PHARMA - EX US, BOARD EXPECTS TO DELIVER AT LEAST MID-TEENS PERCENTAGE REVENUE GROWTH IN 2018 WITH HIGH MARGINAL PROFITABILITY\n* AS IN 2017 GROUP’S REVENUES WILL BE SECOND HALF WEIGHTED IN 2018\n* AT ADJUSTED EBITDA LEVEL, BOARD EXPECTS GROUP TO REMAIN PROFITABLE IN 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T15:00:00.000+03:00",
    "crawled": "2018-05-01T20:08:01.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "sinclair",
        "pharma",
        "plc",
        "fy",
        "gross",
        "profit",
        "increased",
        "million",
        "sinclair",
        "pharma",
        "ex",
        "u",
        "board",
        "expects",
        "deliver",
        "least",
        "percentage",
        "revenue",
        "growth",
        "high",
        "marginal",
        "profitability",
        "group",
        "revenue",
        "second",
        "half",
        "weighted",
        "adjusted",
        "ebitda",
        "level",
        "board",
        "expects",
        "group",
        "remain",
        "profitable",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}